<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute iron poisoning</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute iron poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute iron poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erica L Liebelt, MD, FACMT</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James F Wiley, II, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The epidemiology, pharmacology, clinical manifestations, evaluation, and management of poisoning after acute iron ingestion and iatrogenic intravenous (IV) iron overdose are reviewed here. Iron deficiency, iron requirements, and iron balance are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5925.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5350.html" rel="external">"Iron requirements and iron deficiency in adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">"Regulation of iron balance"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Almost 11,000 iron exposures in children younger than six years of age are reported annually in the United States [<a href="#rid1">1</a>]. The overall number of exposures in this age group is decreasing. In addition, the number of major effects and death in children are improved when compared with the period from 1990 to 2000. However, mortality due to both unintentional and intentional iron ingestions still occurs, pointing to the potential significant toxicity of iron supplements [<a href="#rid1">1</a>].</p><p>The epidemiology varies significantly by the type of ingestion:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unintentional ingestion</strong> – The vast majority of childhood iron poisonings are unintentional and result in no or minimal toxicity. The most serious exposures involve prenatal vitamins and pure iron preparations that contain <a class="drug drug_general" data-topicid="8444" href="/z/d/drug information/8444.html" rel="external">ferrous sulfate</a> tablets, which typically have significantly more elemental iron per tablet (60 to 65 mg) than other iron preparations. These tablets appeal to children because they are often brightly colored, are sugar coated, and have the appearance of candy [<a href="#rid2">2-5</a>]. In one population-based case-control study, the birth of a sibling within six months was identified as a risk factor for iron poisoning in children younger than three years of age (adjusted odds ratio [aOR] 1.9, 95% CI 0.9-3.9); the risk was greatest within the first postpartum month (aOR 3.6, 95% CI 0.8-16.5) [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">Children's chewable vitamins with iron are less likely than adult preparations to cause serious toxicity. There were no fatalities among 195,780 exposures to chewable children's vitamins with iron reported by the American Association of Poison Control Centers between 1983 and 1998 [<a href="#rid6">6</a>]. During the same time period, there were 60 deaths among 147,079 ingestions of adult preparations containing iron. (See <a class="local">'Ingestion of chewable vitamins'</a> below.)</p><p></p><p class="bulletIndent1">Although the majority of patients treated for iron ingestion in health care facilities experience some toxicity, there has been a reduction in the number of fatalities from unintentional exposures [<a href="#rid7">7,8</a>]. This reduced fatality rate has been attributed to the implementation of preventive measures, particularly unit dose packaging, which followed several highly publicized deaths [<a href="#rid2">2,8,9</a>]. These regulations were unfortunately withdrawn in 2003 [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/2873.html" rel="external">"Prevention of poisoning in children", section on 'Primary prevention'</a>.)</p><p></p><p class="bulletIndent1">As with most unintentional ingestions, the best therapy is prevention. Child-resistant closures are required on vitamin bottles that contain more than 250 mg of elemental iron. Nevertheless, some intoxications involve packages or containers that are left open, improperly closed, or opened by a child [<a href="#rid2">2,3</a>]. All medications should be kept in a safe place and stored in their original packaging or in child-resistant containers. Caregivers of children should be instructed to call their regional poison control center (1-800-222-1222) in the event of ingestion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intentional ingestion</strong> – The epidemiology of intentional iron overdose differs from that of unintentional ingestion. In one institutional review of 113 cases of iron overdose requiring hospital admission, 58 percent were determined to be intentional (based upon information provided by the patient, family/caregivers, or friends) [<a href="#rid11">11</a>]. Among the intentional ingestions, 80 percent occurred among females, with a mean age of 19.8 years. The mortality rate is increased among patients with intentional ingestion (10 percent in this series versus less than 1 percent for unintentional iron ingestions).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous (IV) iron overdose</strong> – IV iron overdoses are rare and reflect dosing errors during routine administration [<a href="#rid12">12-15</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h1">PHARMACOLOGY</span></p><p class="headingAnchor" id="H6"><span class="h2">Iron preparations</span></p><p class="headingAnchor" id="H3174590871"><span class="h3">Oral</span><span class="headingEndMark"> — </span>Oral iron preparations are available most commonly in the form of iron salts. The amount of elemental iron in each preparation varies depending upon the salt form  (<a class="graphic graphic_table graphicRef106069" href="/z/d/graphic/106069.html" rel="external">table 1</a>) [<a href="#rid16">16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8443" href="/z/d/drug information/8443.html" rel="external">Ferrous gluconate</a> (12 percent elemental iron)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8444" href="/z/d/drug information/8444.html" rel="external">Ferrous sulfate</a> (20 percent elemental iron)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8442" href="/z/d/drug information/8442.html" rel="external">Ferrous fumarate</a> (33 percent elemental iron)</p><p></p><p>Time-release formulations or enteric-coated iron preparations are available and may have delayed absorption. This is an important consideration when interpreting serum iron levels (SILs). (See <a class="local">'Serum iron level interpretation'</a> below.)</p><p>Iron is an ingredient in many multiple-vitamin preparations. Prenatal vitamins typically contain 60 to 65 mg of elemental iron, whereas most multivitamin preparations contain 15 to 18 mg  (<a class="graphic graphic_table graphicRef73372" href="/z/d/graphic/73372.html" rel="external">table 2</a>). The "placebo" row of some 28-day oral contraceptive pill packages may contain iron and is another potential source for accidental ingestion (eg, the placebo row of Loestrin Fe and Estrostep Fe each contain 75 mg of <a class="drug drug_general" data-topicid="8442" href="/z/d/drug information/8442.html" rel="external">ferrous fumarate</a> [25 mg elemental iron]).</p><p>Nonionic forms of iron include carbonyl iron and iron polysaccharide complex. Carbonyl iron is produced by vaporizing submicroscopic spheres of uncharged, highly purified metallic iron (Feº). Feº must be converted to ferrous iron (Fe2+) by gastric acid before it can be absorbed. As a result, carbonyl iron is absorbed more slowly and has a higher bioavailability than <a class="drug drug_general" data-topicid="8444" href="/z/d/drug information/8444.html" rel="external">ferrous sulfate</a>. In addition, it has a greater safety margin than ferrous sulfate. There have been no published reports of serious or fatal poisoning from ingestion of carbonyl iron [<a href="#rid17">17</a>].</p><p>Iron polysaccharide complex is produced by the neutralization of ferric chloride-carbohydrate solution. It contains 46 percent elemental iron by weight and appears to be less toxic than ferrous salts. In one large retrospective series of iron polysaccharide complex overdose, there were no major effects or deaths reported [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H1299415898"><span class="h3">Intravenous</span><span class="headingEndMark"> — </span>High-molecular-weight (HMW) <a class="drug drug_general" data-topicid="8574" href="/z/d/drug information/8574.html" rel="external">iron dextran</a> was the first available formulation for intramuscular and intravenous (IV) administration, but its use was limited by a high incidence of serious adverse effects, specifically anaphylactic reactions. Several other IV iron compounds have subsequently been developed as safer alternatives to HMW iron dextran  (<a class="graphic graphic_table graphicRef106130" href="/z/d/graphic/106130.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="90237" href="/z/d/drug information/90237.html" rel="external">Ferric carboxymaltose</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8936" href="/z/d/drug information/8936.html" rel="external">Ferric gluconate</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9044" href="/z/d/drug information/9044.html" rel="external">Ferumoxytol</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9004" href="/z/d/drug information/9004.html" rel="external">Iron sucrose</a></p><p class="bulletIndent1"><span class="glyph">●</span>Low-molecular-weight <a class="drug drug_general" data-topicid="8574" href="/z/d/drug information/8574.html" rel="external">iron dextran</a></p><p></p><p>These IV iron preparations are formulated to release iron slowly over many hours to many days. With all of these IV formulations, the iron is tightly bound to carbohydrate carriers, which is important when interpreting SILs because the iron level obtained does not reflect free, circulating iron. (See <a class="local">'IV iron overdose'</a> below.)</p><p>The use of these preparations for the treatment of iron deficiency are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Intravenous iron'</a> and  <a class="medical medical_review" href="/z/d/html/15647.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Treatment", section on 'Intravenous iron therapy'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Toxic dose</span><span class="headingEndMark"> — </span>The toxic dose of iron is determined by the route of exposure and the iron formulation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral</strong> – The toxicity of oral iron depends upon the amount of elemental iron ingested. Various salt forms contain different percentages of elemental iron  (<a class="graphic graphic_table graphicRef106069" href="/z/d/graphic/106069.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef73372" href="/z/d/graphic/73372.html" rel="external">table 2</a>) (see <a class="local">'Iron preparations'</a> above). As an example, a 15-kg child who ingests 10 tablets, each containing 325 mg of <a class="drug drug_general" data-topicid="8444" href="/z/d/drug information/8444.html" rel="external">ferrous sulfate</a>, has taken about 43 mg/kg of elemental iron.</p><p></p><p class="bulletIndent1">The minimum toxic dose and the lethal doses of oral and IV iron are not firmly established. The following symptoms and toxicities have been reported at various doses:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who ingest less than 20 mg/kg of elemental iron are usually asymptomatic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ingestions of 20 to 60 mg/kg of elemental iron have a low potential for serious toxicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A small number of patients who have taken 40 to 60 mg/kg of elemental iron are symptomatic. In one retrospective review of 199 acute iron exposures, none of the patients who ingested between 40 and 60 mg/kg of iron developed serious toxicity [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ingestions ≥60 mg/kg of elemental iron are associated with serious toxicity and death [<a href="#rid2">2,16,20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV</strong> – Because of their unique structure, which reduces the potential for unbound iron in the circulation, IV iron preparations appear to have a lower likelihood of toxicity than oral preparations [<a href="#rid22">22,23</a>]. For example, in mice, the median lethal dose (LD<sub>50</sub>) ranges from 155 to &gt;1000 mg/kg elemental iron, depending upon the specific compound [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Iron toxicity</span><span class="headingEndMark"> — </span>Ferric iron (Fe3+) is toxic to many cellular processes. The primary mechanism for iron-induced tissue damage is free radical production and lipid peroxidation [<a href="#rid24">24</a>]. Toxic effects on cells include the following [<a href="#rid16">16,20,25,26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mucosal cell necrosis</p><p class="bulletIndent1"><span class="glyph">●</span>Impairment of capillary permeability</p><p class="bulletIndent1"><span class="glyph">●</span>Alteration of the lipid membrane of mitochondria</p><p class="bulletIndent1"><span class="glyph">●</span>Inhibition of enzymatic processes in the Krebs cycle</p><p class="bulletIndent1"><span class="glyph">●</span>Uncoupling of oxidative phosphorylation</p><p class="bulletIndent1"><span class="glyph">●</span>Direct vasodilation</p><p class="bulletIndent1"><span class="glyph">●</span>Inhibition of serum proteases (eg, thrombin)</p><p></p><p>Normally, transferrin (the chief iron-binding protein in plasma) and ferritin (an iron-storage protein that sequesters iron intracellularly) protect cells by binding iron, limiting the amount that is circulating in the ferric state. However, these protective mechanisms become quickly overwhelmed with an acute intoxication [<a href="#rid27">27</a>].</p><p>After iron ingestion, local toxicity (manifested as abdominal pain, vomiting, diarrhea, and gastrointestinal [GI] bleeding) develops from iron-induced damage to the GI mucosa. Systemic toxicity occurs as the result of injury to the cardiovascular system and liver. The cause of death from iron poisoning is usually shock or liver failure [<a href="#rid24">24</a>]. (See <a class="local">'Clinical manifestations'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h2">Kinetics</span><span class="headingEndMark"> — </span>Iron kinetics vary according to the route of administration:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral</strong> – Iron is absorbed primarily in the duodenum and upper jejunum. It crosses cell membranes only in the ferrous state (Fe2+). Once absorbed by the mucosal cells, iron is oxidized to the ferric (Fe3+) form. From the enterocyte, iron is released into the plasma and bound to transferrin.</p><p></p><p class="bulletIndent1">After therapeutic dosing, 10 to 35 percent of iron is absorbed. As much as 80 to 95 percent may be absorbed in iron-deficient patients [<a href="#rid24">24,27</a>]. The absorption of enteric-coated preparations is less than that of non-enteric-coated preparations.</p><p></p><p class="bulletIndent1">The amount of iron that is absorbed in an overdose situation is unknown [<a href="#rid25">25</a>]. Physiologic regulation of iron absorption is lost in the setting of excessive iron ingestions. In addition, normal protective mechanisms (transport and storage proteins) become saturated, resulting in more free-circulating iron (which is responsible for cellular toxicity).</p><p></p><p class="bulletIndent1">Peak SILs occur two to three hours after therapeutic dosing and four to six hours after ingestion of an overdose [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">Absorbed iron is rapidly cleared from the circulation and taken up by the cells of various tissues, where high concentrations of iron disrupt mitochondrial function [<a href="#rid26">26,28</a>]. For the most part, entry of iron into the tissues is an active, saturable process; the liver is unique in that it also can passively absorb iron [<a href="#rid29">29,30</a>]. Because of the liver's capacity to absorb considerable quantities of iron, the half-life of iron after therapeutic and toxic dosing is similar (approximately six hours) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">There are no physiologic mechanisms for iron excretion. Iron may be lost via the constant sloughing of intestinal cells, as well as menstrual bleeding in menarchal women.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenteral</strong> – IV formulations are made up of complexes of iron and carbohydrate nanoparticles that keep the iron compound stable until it is delivered to macrophages in the reticuloendothelial system that are primarily located in the liver, spleen, and bone marrow. There, the iron is released over time according to the specific iron compound and then either stored in the cytoplasm or transported by transferrin for incorporation into hemoglobin [<a href="#rid23">23</a>]. The iron-carbohydrate complex is kinetically robust for all formulations except for <a class="drug drug_general" data-topicid="8936" href="/z/d/drug information/8936.html" rel="external">ferric gluconate</a>. Kinetically robust compounds are less likely to rapidly release ferric iron (Fe3+) and exceed transferrin-binding capacity. These compounds also permit large doses (eg, up to 2 g for iron isomaltoside) and infusion times as short as 15 to 20 minutes [<a href="#rid22">22,23</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The manifestations of iron toxicity after ingestion are typically described in five (often overlapping) phases  (<a class="graphic graphic_table graphicRef61711" href="/z/d/graphic/61711.html" rel="external">table 4</a>) [<a href="#rid16">16,19-21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Early gastrointestinal (GI) symptoms: 30 minutes to 6 hours after ingestion</p><p class="bulletIndent1"><span class="glyph">●</span>Latent (or relative stability): 6 to 24 hours after ingestion</p><p class="bulletIndent1"><span class="glyph">●</span>Shock and persistent elevated anion gap metabolic acidosis: 6 to 72 hours after ingestion</p><p class="bulletIndent1"><span class="glyph">●</span>Delayed hepatotoxicity/hepatic necrosis: 12 to 96 hours after ingestion</p><p class="bulletIndent1"><span class="glyph">●</span>Remote bowel obstruction (usually gastric outlet obstruction): 2 to 8 weeks after ingestion</p><p></p><p>The progression of these phases may occur rapidly after large oral overdoses. Therefore, the clinical phase should be determined by the patient's clinical and laboratory manifestations, <strong>not</strong> by the time since the ingestion:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal phase</strong> – The GI phase occurs between 30 minutes and 6 hours after ingestion. The clinical manifestations of this phase are the result of direct injury to the GI mucosa. Signs and symptoms may include abdominal pain, vomiting, diarrhea, hematemesis, melena, lethargy, shock (from capillary leak and third spacing), and metabolic acidosis. Vomitus and stools may be dark gray, green, or black due to the presence of disintegrating iron tablets. Vomiting is the most sensitive indicator of serious ingestions. Death in this phase is usually caused by hypovolemic shock [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">Most patients with mild to moderate iron toxicity do not progress beyond this phase, and their symptoms may resolve within four to six hours. If no GI symptoms develop within six hours of a presumed iron ingestion, it is unlikely that iron toxicity will occur. Ingestion of enteric-coated iron tablets is an exception to the "six-hour rule."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Latent phase</strong> – The latent phase (sometimes also referred to as the "relative stability" or "quiescent" phase) occurs from 6 to 24 hours after ingestion and is a period of apparent recovery. The resolution of GI symptoms is presumed to occur as circulating free iron is redistributed into the reticuloendothelial systems.</p><p></p><p class="bulletIndent1">This phase may be transient or may not appear at all in patients with severe iron poisoning. Patients appear stable, but they may not be asymptomatic. Careful evaluation may reveal poor perfusion, hyperventilation (secondary to metabolic acidosis), and oliguria (secondary to hypovolemia) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">It is critical to differentiate patients who are in this phase from those with low-toxicity ingestions who have exhibited only mild GI symptoms and for whom toxicity has now resolved. Patients whose GI symptoms have improved should be observed and re-evaluated to determine whether they have truly recovered or are progressing to further clinical deterioration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shock and metabolic acidosis</strong> – Cardiovascular toxicity (manifested as shock, pallor, tachycardia, and/or hypotension) may develop. Coagulopathy (preceding liver dysfunction) can occur because of iron's effect (as a protease inhibitor) on prothrombin [<a href="#rid32">32,33</a>].</p><p></p><p class="bulletIndent1">The etiology of the shock state may be hypovolemic, distributive, or cardiogenic, depending on the time of onset [<a href="#rid24">24</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypovolemic shock, due to fluid and blood losses, occurs within the first few hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Distributive shock develops a few hours later. The etiology is poorly understood. Decreased vascular tone and increased vascular permeability may be caused primarily by iron or possibly ferritin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiogenic shock develops within 24 to 48 hours after the ingestion due to the depressant effect of iron on myocardial cells.</p><p></p><p class="bulletIndent1">Metabolic acidosis is often profound and is an indicator of iron-induced toxicity. It is caused, at least in part, by hydration of absorbed ferric ions, which releases three protons (Fe3<sup>+</sup> + 3H2O —&gt; Fe(OH)<sup>3</sup> + 3H<sup>+</sup>) [<a href="#rid24">24</a>]. Lactic acidosis may also occur as the result of hypovolemia/poor tissue perfusion and iron-induced mitochondrial dysfunction.</p><p></p><p class="bulletIndent1">The following clinical features, leading to multisystem organ failure, can be seen in the shock and metabolic acidosis phase:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GI hemorrhage, with hematemesis and melena, may recur. Bowel perforation may develop.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Progressive pulmonary dysfunction (acute lung injury or the acute respiratory distress syndrome) is a distinguishing characteristic of this phase. The etiology likely includes free radical production, causing capillary leak, along with hypotension and metabolic acidosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An iron-induced coagulopathy may worsen bleeding and hypovolemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Renal and neurologic dysfunction can develop during this phase.</p><p></p><p class="bulletIndent1">Patients may develop jaundice, coma, and worsening coagulopathy from hepatic dysfunction. Death in this third phase is caused by widespread cellular dysfunction, which results from mitochondrial disruption [<a href="#rid31">31</a>]. Once a critical amount of iron has reached the mitochondria, therapy has little effect and outcome is poor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatotoxicity/hepatic necrosis</strong> – The onset of hepatotoxicity is usually within two days of ingestion. Although hepatic necrosis does not occur in all iron-poisoned patients, it may develop within 12 to 96 hours after ingestion. The liver is particularly vulnerable to iron toxicity for several reasons: it is exposed to high concentrations of iron through the portal circulation, it absorbs iron passively, and hepatocytes have high metabolic activity. Liver failure is the second most common cause of death from iron poisoning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bowel obstruction</strong> – Bowel obstruction occurs as the result of GI scarring. Symptoms typically develop two to eight weeks after the ingestion. The classic location for GI obstruction is the gastric outlet, since this is where iron tablets aggregate and damage tissue, with subsequent scar tissue formation [<a href="#rid24">24,34</a>]. Vomiting is the presenting symptom of this late sequela.</p><p></p><p class="bulletIndent1">Serious iron toxicity from iatrogenic overdose of intravenous (IV) iron preparations, while theoretically possible, has not occurred despite overdoses of up to 10 times normal dosing. (See <a class="local">'IV iron overdose'</a> below.)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H1021207352"><span class="h2">Approach</span><span class="headingEndMark"> — </span>Evaluation and management of acute iron ingestion is provided in the algorithms for symptomatic and asymptomatic patients  (<a class="graphic graphic_algorithm graphicRef131898 graphicRef131897" href="/z/d/graphic/131898.html" rel="external">algorithm 1A-B</a>) and the rapid overview table  (<a class="graphic graphic_table graphicRef61711" href="/z/d/graphic/61711.html" rel="external">table 4</a>).</p><p>Although iatrogenic overdoses involving intravenous (IV) iron preparations have occurred, serious poisoning has not been described. (See <a class="local">'IV iron overdose'</a> below.)</p><p class="headingAnchor" id="H2378886819"><span class="h2">Stabilization</span><span class="headingEndMark"> — </span>Patients who require resuscitation must be rapidly identified, and receive appropriate treatment including airway protection, respiratory support, and volume resuscitation. (See  <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">"Approach to the child with occult toxic exposure", section on 'Initial evaluation and stabilization'</a>.)</p><p>Patients with moderate to severe iron poisoning often require fluid resuscitation with isotonic crystalloid (eg, normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) for hypovolemic shock during the early phases of treatment. (See  <a class="medical medical_review" href="/z/d/html/6389.html" rel="external">"Hypovolemic shock in children in resource-abundant settings: Initial evaluation and management"</a> and  <a class="medical medical_review" href="/z/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">History</span><span class="headingEndMark"> — </span>The following historical information is essential for determining the significance of an iron ingestion and directing further management:</p><p class="bulletIndent1"><span class="glyph">●</span>What type of iron was taken, and how much? One determinant of the severity of an overdose is the mg/kg of elemental iron that was ingested and the formulation of iron. What was the specific IV iron preparation? (See <a class="local">'Iron preparations'</a> above and <a class="local">'Toxic dose'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When did the ingestion occur? Symptoms of iron intoxication generally develop soon after the ingestion. Patients who have not developed symptoms within six hours are unlikely to have ingested a significant amount of iron unless they have ingested an enteric-coated preparation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Was the ingestion unintentional or intentional? An intentional ingestion, whether as a suicide attempt/gesture or as a form of child abuse, is more likely to be significant [<a href="#rid35">35</a>]. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Did the patient have access to other toxic substances? For children, are there other children at home who could have also ingested iron [<a href="#rid20">20</a>]?</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Initial physical findings of iron poisoning include:</p><p class="bulletIndent1"><span class="glyph">●</span>Tachycardia with poor peripheral perfusion (prolonged capillary refill time and/or diminished pulses); hypotension reflects uncompensated hypovolemic shock</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tachypnea due to metabolic acidosis with lungs clear to auscultation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epigastric abdominal tenderness with vomiting and diarrhea; hematemesis and/or melena may also be present</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lethargy or coma </p><p></p><p>Subtle findings, including signs of poor perfusion (such as lethargy and tachycardia), metabolic acidosis (tachypnea), or gastrointestinal (GI) symptoms (abdominal tenderness, persistent vomiting, or diarrhea) may identify a patient with a significant ingestion who has progressed to the latent phase. (See <a class="local">'Clinical manifestations'</a> above.)</p><p class="headingAnchor" id="H20"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>The purpose of the laboratory evaluation is to confirm the diagnosis of iron poisoning and to monitor for clinical effects (such as metabolic acidosis, liver injury, coagulopathy, and anemia). </p><p class="headingAnchor" id="H830182630"><span class="h3">Symptomatic patients</span><span class="headingEndMark"> — </span>Symptomatic patients require the following laboratory studies according to the degree of poisoning  (<a class="graphic graphic_algorithm graphicRef131898" href="/z/d/graphic/131898.html" rel="external">algorithm 1A</a>) [<a href="#rid3">3,16,28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild poisoning (nausea, self-limited vomiting, and/or mild abdominal pain):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Plasma glucose</p><p class="bulletIndent2"><span class="glyph">•</span>Serum electrolytes</p><p class="bulletIndent2"><span class="glyph">•</span>Blood urea nitrogen (BUN) and creatinine</p><p class="bulletIndent2"><span class="glyph">•</span>Venous or arterial blood gas</p><p class="bulletIndent2"><span class="glyph">•</span>Peak serum iron level (SIL) (see <a class="local">'Serum iron level interpretation'</a> below):</p><p class="bulletIndent3"><span class="glyph">-</span>Four to six hours after ingestion of regular iron</p><p class="bulletIndent3"><span class="glyph">-</span>Eight hours after ingestion of extended-release iron  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate to severe poisoning (persistent vomiting, hypovolemic shock, and/or altered mental status [lethargy or coma]):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All studies as above for mild poisoning <strong>and</strong></p><p class="bulletIndent2"><span class="glyph">•</span>Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin</p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count (CBC) with differential</p><p class="bulletIndent2"><span class="glyph">•</span>Prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR)</p><p class="bulletIndent2"><span class="glyph">•</span>Type and screen if clinical evidence of bleeding</p><p></p><p>All symptomatic patients should also undergo an emergency plain radiograph of the abdomen. (See <a class="local">'Plain radiograph of the abdomen'</a> below.)</p><p>An elevated anion gap metabolic acidosis is an important but nonspecific predictor of iron toxicity and is an indication for treatment with <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a>. (See <a class="local">'Deferoxamine'</a> below.)</p><p>Although leukocytosis (white blood cell count &gt;15,000 cells/microL) and hyperglycemia (&gt;150 mg/dL) are associated with SILs greater than 300 mcg/dL, they are nonspecific [<a href="#rid36">36,37</a>]. More importantly, the absence of leukocytosis or hyperglycemia <strong>cannot</strong> be used to exclude iron toxicity.</p><p>Of note, total serum iron binding capacity (TIBC) should <strong>not</strong> be used to manage patients with iron overdose [<a href="#rid9">9</a>]. TIBC measures the amount of iron in the blood that can be bound to transferrin. In theory, there should be no free iron when TIBC is greater than the SIL. However, laboratory methods used to measure TIBC are inaccurate in patients with iron overdose. In addition, <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> interferes with the measurement of TIBC. Finally, multiple case reports have described iron toxicity in cases where the TIBC was greater than SIL [<a href="#rid38">38-40</a>].</p><p class="headingAnchor" id="H1373340609"><span class="h3">Asymptomatic patients</span><span class="headingEndMark"> — </span>All asymptomatic patients who present to the emergency department and have ingested more than a trivial amount of iron require observation for the development of symptoms and measurement of a peak SIL  (<a class="graphic graphic_algorithm graphicRef131897" href="/z/d/graphic/131897.html" rel="external">algorithm 1B</a>) (see <a class="local">'Serum iron level interpretation'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Regular iron: Four to six hours after ingestion</p><p class="bulletIndent1"><span class="glyph">●</span>Extended-release iron: Eight hours after ingestion</p><p></p><p>In addition to a SIL, asymptomatic patients at risk for toxicity (ingestion of an unknown amount of iron, an estimated dose ≥40 mg/kg elemental iron, or an intentional ingestion) also require prompt measurement of the following laboratory studies at the time of presentation [<a href="#rid3">3,16,28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma glucose</p><p class="bulletIndent1"><span class="glyph">●</span>Serum electrolytes</p><p class="bulletIndent1"><span class="glyph">●</span>BUN and creatinine</p><p class="bulletIndent1"><span class="glyph">●</span>Venous or arterial blood gas</p><p></p><p>These patients should also undergo an emergency plain radiograph of the abdomen. (See <a class="local">'Plain radiograph of the abdomen'</a> below.)</p><p>Asymptomatic patients with a peak SIL ≥500 mcg/dL (90 micromol/L) or the presence of a high anion gap metabolic acidosis require treatment with <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> (see <a class="local">'Deferoxamine'</a> below) and measurement of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>ALT, AST, and total bilirubin</p><p class="bulletIndent1"><span class="glyph">●</span>CBC with differential</p><p class="bulletIndent1"><span class="glyph">●</span>PT, PTT, and INR</p><p></p><p class="headingAnchor" id="H21"><span class="h3">Serum iron level interpretation</span><span class="headingEndMark"> — </span>Measurement of a peak SIL is useful for confirming the diagnosis of iron ingestion. It may also be helpful in predicting serious toxicity but only if blood samples are drawn at the appropriate time: four to six hours after ingestion of regular iron formulations and eight hours after ingestion of extended-release iron [<a href="#rid21">21,24</a>]. Because iron is rapidly cleared from the serum, levels obtained after eight hours may be deceivingly low. Interpretation of iron levels after iatrogenic IV iron overdose is discussed separately. (See <a class="local">'IV iron overdose'</a> below.)</p><p>Peak SILs typically correlate with the following levels of toxicity after oral iron overdose:</p><p class="bulletIndent1"><span class="glyph">●</span>Less than 350 mcg/dL (63 micromol/L) – Minimal toxicity</p><p class="bulletIndent1"><span class="glyph">●</span>Between 350 and 500 mcg/dL (63 and 90 micromol/L) – Mild to moderate GI symptoms (rarely develop serious complications) [<a href="#rid3">3</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Greater than 500 mcg/dL (90 micromol/L) – Serious systemic toxicity</p><p class="bulletIndent1"><span class="glyph">●</span>Greater than 1000 mcg/dL (179 micromol/L) – Significant morbidity and mortality [<a href="#rid16">16,20,21,38,41</a>]</p><p></p><p>However, the correlation of SIL with the severity or the clinical phase of iron intoxication is not exact because it measures free iron circulating in the blood. It is intracellular iron that causes systemic toxicity. Several retrospective series have reported patients with SILs greater than 500 mcg/dL (90 micromol/L) who were asymptomatic, as well as patients with cardiovascular instability with SILs less than 500 mcg/dL (90 micromol/L) [<a href="#rid19">19,38,41</a>]. These lower levels may not have represented peak SILs. Although iron is rapidly absorbed, absorption from the ingestion of sustained-release tablets, enteric-coated tablets, or ongoing release of iron from concretions of pills may be delayed. These reports illustrate the fact that there is no test (including SIL) that is superior to the clinical status of the patient for determining the severity of an iron ingestion.</p><p>Previously, the <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> challenge test was proposed as an alternative method of identifying the presence of circulating ferric iron. It consisted of administering an intramuscular dose of deferoxamine and waiting to see if the patient developed "vin rosé" or brick iron urine indicating the presence of ferrioxamine that is created by binding of deferoxamine to free iron. However, multiple reports have identified patients with an SIL greater than 500 mcg/dL whose urine did not change color with deferoxamine [<a href="#rid42">42</a>]. Thus, the deferoxamine challenge test is no longer recommended to confirm the ingestion of a toxic dose of iron or to guide management.</p><p class="headingAnchor" id="H24"><span class="h2">Plain radiograph of the abdomen</span><span class="headingEndMark"> — </span>In addition to laboratory studies (see <a class="local">'Laboratory studies'</a> above), the following patients require a plain anterior-posterior (AP) radiograph of the abdomen:</p><p class="bulletIndent1"><span class="glyph">●</span>Any symptoms of poisoning</p><p class="bulletIndent1"><span class="glyph">●</span>Ingestion of an unknown amount of iron or estimated ingestion of more than 40 mg/kg of elemental iron </p><p class="bulletIndent1"><span class="glyph">●</span>Intentional ingestion of iron</p><p></p><p>The presence of radiopaque pills in the stomach confirms the ingestion of iron  (<a class="graphic graphic_diagnosticimage graphicRef68584" href="/z/d/graphic/68584.html" rel="external">image 1</a>) and is used to determine further management  (<a class="graphic graphic_algorithm graphicRef131897" href="/z/d/graphic/131897.html" rel="external">algorithm 1B</a> and <a class="graphic graphic_algorithm graphicRef131898" href="/z/d/graphic/131898.html" rel="external">algorithm 1A</a>). (See <a class="local">'Gastrointestinal decontamination'</a> below.)</p><p>The radiopacity of iron tablets depends on the type of formulation and content of elemental iron. Many liquid iron preparations and chewable vitamins with iron (which have low concentrations of iron) are not visible. Consequently, the presence of few or no pills does not necessarily mean that the ingestion was insignificant. This was demonstrated in a retrospective review describing 93 children with iron ingestions (55 percent chewable tablets, 40 percent non-chewable tablets). Abdominal radiographs were obtained in 54 patients [<a href="#rid43">43</a>]. Radiopaque densities were visualized in only one case.</p><p>Patients with a significant iron overdose who have no radiopaque pills seen on plain radiograph are unlikely to benefit from GI decontamination [<a href="#rid44">44-46</a>]. (See <a class="local">'Gastrointestinal decontamination'</a> below.)</p><p class="headingAnchor" id="H305127599"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of iron poisoning is suspected based upon a history of iron ingestion and clinical manifestations of poisoning such as persistent vomiting and diarrhea, hypovolemic shock, altered mental status, and/or unexplained metabolic acidosis. It is confirmed by the presence of visible iron pills on plain abdominal radiograph or a peak serum iron level (SIL) ≥500 mcg/dL (90 micromol/L). A peak SIL also helps to identify the level of expected toxicity after an oral overdose and guides management decisions. (See <a class="local">'Serum iron level interpretation'</a> above.)</p><p class="headingAnchor" id="H4236182684"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Other agents that can cause vomiting with toxic ingestion include salicylates, <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a>, caustic agents, isopropanol, arsenic and mercurial salts, organophosphate and carbamate compounds, nicotine, nonsteroidal antiinflammatory drugs (NSAIDs), mushrooms, and <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid16">16</a>]. In many instances, the history helps to distinguish iron from these toxins. When history is lacking, an elevated peak serum iron level (SIL; ≥500 mcg/dL [90 micromol/L]) identifies iron as the cause of serious toxicity. In addition, characteristic signs other than vomiting and, with selected agents, laboratory findings, help to distinguish these poisons from iron:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salicylates</strong> – Elevated plasma salicylate concentration, especially when associated with hyperthermia and hyperventilation (see  <a class="medical medical_review" href="/z/d/html/329.html" rel="external">"Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">Theophylline</a> – Elevated theophylline level, especially when associated with seizures and tachyarrhythmias (see  <a class="medical medical_review" href="/z/d/html/6501.html" rel="external">"Theophylline poisoning"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Organophosphates or carbamates</strong> – Muscarinic signs in addition to vomiting and diarrhea (ie, bronchorrhea, bronchospasm, bradycardia, miosis, or excessive tearing and oral sections), cardiac arrhythmias, muscle fasciculations with weakness, and seizures in association with decreased red blood cell acetylcholinesterase (see  <a class="medical medical_review" href="/z/d/html/339.html" rel="external">"Organophosphate and carbamate poisoning"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nicotine</strong> – Muscarinic signs in addition to vomiting and diarrhea (ie, bronchorrhea, bronchospasm, bradycardia, miosis, or excessive tearing and oral sections), seizures, muscle weakness, and rhabdomyolysis (see  <a class="medical medical_review" href="/z/d/html/130609.html" rel="external">"Nicotine poisoning (e-cigarettes, tobacco products, plants, and pesticides)", section on 'Clinical features of poisoning'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSAIDS</strong> – Serious toxicity occurring only after very large ingestions and consisting of anion gap metabolic acidosis, depressed mental status, and cardiac arrhythmia (see  <a class="medical medical_review" href="/z/d/html/341.html" rel="external">"Nonsteroidal antiinflammatory drug (NSAID) poisoning"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mushrooms</strong> – History of mushroom ingestion with vomiting followed by characteristic mushroom syndrome  (<a class="graphic graphic_table graphicRef77875" href="/z/d/graphic/77875.html" rel="external">table 5</a>) (see  <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">"Clinical manifestations and evaluation of mushroom poisoning"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">Colchicine</a> – History of colchicine ingestion (medication or plant) associated with onset of multisystem organ failure (see  <a class="medical medical_review" href="/z/d/html/6507.html" rel="external">"Potentially toxic plant ingestions in children: Clinical manifestations and evaluation", section on 'Gastroenteritis with systemic toxicity'</a>)</p><p></p><p>Iron poisoning should also be considered for patients who present with vomiting, abdominal pain, and an elevated anion gap metabolic acidosis without an obvious medical cause, even in the absence of a history of ingestion. The approach to metabolic acidosis, including causes of elevated anion gap metabolic acidosis, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6100.html" rel="external">"Approach to the child with metabolic acidosis"</a> and  <a class="medical medical_review" href="/z/d/html/2291.html" rel="external">"Approach to the adult with metabolic acidosis"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of iron poisoning after acute ingestion is determined by the presence of and degree of symptoms on initial presentation and is provided in the algorithms for symptomatic and asymptomatic patients  (<a class="graphic graphic_algorithm graphicRef131898" href="/z/d/graphic/131898.html" rel="external">algorithm 1A</a> and <a class="graphic graphic_algorithm graphicRef131897" href="/z/d/graphic/131897.html" rel="external">algorithm 1B</a>)and the rapid overview  (<a class="graphic graphic_table graphicRef61711" href="/z/d/graphic/61711.html" rel="external">table 4</a>).</p><p class="headingAnchor" id="H603303028"><span class="h2">Moderate to severe poisoning</span><span class="headingEndMark"> — </span>Patients at risk for serious systemic toxicity should receive treatment to limit further absorption of iron. Indications of potential serious toxicity include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Ingestion of ≥60 mg/kg of elemental iron by history or based upon pills visible on plain radiograph of the abdomen</p><p class="bulletIndent1"><span class="glyph">●</span>Peak serum iron level (SIL) ≥500 mcg/dL (90 micromol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent serious symptoms such as vomiting, diarrhea, and/or altered mental status</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic symptoms, including subtle symptoms that can be seen in the latent phase, such as tachycardia, poor perfusion, tachypnea, and/or hypotension (see <a class="local">'Clinical manifestations'</a> above)</p><p></p><p>SIL may not be rapidly available at some institutions. In this situation, the decision to proceed with aggressive gastrointestinal (GI) decontamination and/or initiate <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> therapy must be made based on the amount of elemental iron ingested, presence of systemic symptoms, and findings on abdominal radiograph. (See <a class="local">'Gastrointestinal decontamination'</a> below and <a class="local">'Deferoxamine'</a> below.)</p><p>Systemic symptoms must be distinguished from local GI symptoms. Many patients with SILs &lt;500 mcg/dL (90 micromol/L) may have some abdominal pain, vomiting, and/or diarrhea as the result of GI irritation. In contrast to systemic symptoms, GI symptoms generally do not require fluid resuscitation, although smaller children may develop significant, protracted vomiting and diarrhea. (See <a class="local">'Mild poisoning'</a> below.)</p><p class="headingAnchor" id="H27"><span class="h3">Supportive care</span><span class="headingEndMark"> — </span>Airway protection and respiratory support should be provided as needed. (See  <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">"Approach to the child with occult toxic exposure", section on 'Initial evaluation and stabilization'</a>.)</p><p>Volume resuscitation to maintain euvolemia is essential. Hypovolemic shock is the major cause of mortality during the first phase of iron intoxication. Patients who present with severe GI-phase symptoms require urgent intensive management to maintain effective circulating blood volume [<a href="#rid3">3,31</a>] (see <a class="local">'Clinical manifestations'</a> above). Intravenous (IV) access should be obtained. Normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> should be administered in boluses of 20 mL/kg as necessary to improve perfusion and tachycardia, and to maintain blood pressure. (See  <a class="medical medical_review" href="/z/d/html/6389.html" rel="external">"Hypovolemic shock in children in resource-abundant settings: Initial evaluation and management"</a>.)</p><p>Although uncommon, patients with serious upper GI bleeding warrant consultation with a pediatric gastroenterologist and serial measurement of hemoglobin to determine the need for transfusion therapy. (See  <a class="medical medical_review" href="/z/d/html/5857.html" rel="external">"Approach to upper gastrointestinal bleeding in children"</a>.)</p><p>Patients who require supportive care as the result of iron ingestion are likely experiencing significant toxicity. Further evaluation and treatment are necessary. (See <a class="local">'Evaluation'</a> above and <a class="local">'Deferoxamine'</a> below and <a class="local">'Gastrointestinal decontamination'</a> below.)</p><p class="headingAnchor" id="H29"><span class="h3">Gastrointestinal decontamination</span><span class="headingEndMark"> — </span>Because iron does not bind to activated charcoal, GI decontamination for acute iron poisoning consists of whole-bowel irrigation (WBI) and, rarely, orogastric lavage or other means (eg, upper endoscopy or gastrotomy) to remove large numbers of iron pills from the stomach as determined by pills seen on plain abdominal radiograph  (<a class="graphic graphic_algorithm graphicRef131898" href="/z/d/graphic/131898.html" rel="external">algorithm 1A</a> and <a class="graphic graphic_algorithm graphicRef131897" href="/z/d/graphic/131897.html" rel="external">algorithm 1B</a>) [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Orogastric lavage</strong> – In most patients, the risk of gastric lavage following iron overdose outweighs the limited benefit. However, orogastric lavage with normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> via a large-bore orogastric tube may be indicated for patients with moderate to severe iron poisoning and large amounts of iron still unabsorbed in the stomach (eg, 20 to 30 pills visible on abdominal radiograph). Gastric lavage carries a significant risk of complications including aspiration, esophageal or gastric perforation, and laryngospasm. Patients who cannot protect their airway require rapid sequence intubation prior to the procedure. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Gastric lavage'</a>.)</p><p></p><p class="bulletIndent1">A repeat radiograph should be obtained to evaluate the efficacy of gastric evacuation and to determine whether further decontamination measures are necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>WBI</strong> – GI decontamination with WBI has the potential to remove iron from the intestine before absorption and tissue uptake can occur [<a href="#rid44">44</a>]. We suggest WBI rather than no GI decontamination for the following patients in whom the amount of unabsorbed iron based upon the number of pills seen on radiograph and the elemental iron content of the product ingested  (<a class="graphic graphic_table graphicRef106069" href="/z/d/graphic/106069.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef73372" href="/z/d/graphic/73372.html" rel="external">table 2</a>) has the potential for worsening toxicity based upon patient weight (see <a class="local">'Toxic dose'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptoms of moderate to severe iron poisoning</p><p class="bulletIndent2"><span class="glyph">•</span>High anion gap metabolic acidosis</p><p class="bulletIndent2"><span class="glyph">•</span>Peak SIL ≥500 mcg/dL (90 micromol/L)</p><p class="bulletIndent2"><span class="glyph">•</span>Patients who have a continued rise in SILs despite administration of <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a></p><p class="bulletIndent2"><span class="glyph">•</span>Asymptomatic or mildly symptomatic patients with an estimated ingested dose ≥60 mg/kg elemental iron based on the number of visible pills on radiograph.</p><p></p><p class="bulletIndent1">The procedure for performing WBI, as well as the contraindications and complications, is described separately (see  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Whole bowel irrigation'</a>). In patients with iron poisoning, effective WBI requires placement of a nasogastric tube, control of emesis, and concomitant management of shock. Serial abdominal radiographs (eg, every 12 hours) during WBI may be useful in determining the efficacy of WBI. The endpoints of treatment are improved clinical status, a clear rectal effluent, and the absence of iron tablets or significantly decreased number of tablets seen on repeat abdominal radiograph [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1">Case reports and case series have described improved outcomes for patients with iron poisoning who received WBI [<a href="#rid9">9,47-50</a>]. Most of the patients also received <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> therapy. Consequently, the effect of WBI, independent of deferoxamine, is difficult to ascertain. On the other hand, there have been no reports of significant complications from WBI. Patients with vomiting and an unprotected airway are at risk of aspiration, but this has not been reported as a direct result of WBI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Upper GI endoscopy or surgical gastrotomy</strong> – Iron tablets may become embedded in the gastric wall, forming bezoars or pseudo-concretions that are resistant to lavage and/or WBI. In such cases, endoscopy or surgical gastrotomy may have benefit, especially when clinical toxicity persists. Case reports have described surgical removal of iron from the stomach (gastrotomy) for pill concretions that could not be removed with other methods of GI decontamination [<a href="#rid51">51,52</a>]. Endoscopic removal of a large number of pills or pill concretions may also be attempted, providing an alternative to a major surgical operative procedure. Chelation therapy along with supportive care should continue.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatments to avoid</strong> – Other forms of GI decontamination that should <strong>not</strong> be performed after iron overdose include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Activated charcoal because it binds iron poorly and is ineffective</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Syrup of ipecac to induce vomiting because it is ineffective in general, and iron ingestion frequently causes spontaneous vomiting (see  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Outdated treatments'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastric lavage with bicarbonate or phosphate solutions because of the large volume of bicarbonate necessary to achieve effect and reports of phosphate poisoning [<a href="#rid20">20,53-56</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastric lavage with <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> because of the large volumes required in an overdose to have any appreciable effect</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Catharsis via the administration of magnesium-containing preparations (eg, milk of magnesia) because it is ineffective [<a href="#rid21">21,57</a>]</p><p></p><p class="headingAnchor" id="H30"><span class="h3">Deferoxamine</span><span class="headingEndMark"> — </span>IV <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> is the antidote of choice for serious iron overdose. It is a chelating agent that, in acute iron intoxication, binds with ferric iron (Fe3+) in the blood to form water-soluble ferrioxamine that is then excreted by the kidneys. Ferrioxamine gives urine the classically described "vin rosé" color, which appears as orange to reddish brown. Deferoxamine must be administered early in the treatment, preferably as soon as the potential for serious poisoning is recognized, because iron moves rapidly from the circulation into cells where, in acute intoxication, it is not readily accessible for chelation. (See <a class="local">'Kinetics'</a> above.)</p><p>We recommend IV <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> for patients with an oral iron overdose and any one of the following signs of serious poisoning  (<a class="graphic graphic_algorithm graphicRef131898" href="/z/d/graphic/131898.html" rel="external">algorithm 1A</a> and <a class="graphic graphic_algorithm graphicRef131897" href="/z/d/graphic/131897.html" rel="external">algorithm 1B</a>) [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe symptoms (hypovolemia/shock, lethargy/coma, persistent vomiting/diarrhea)</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated anion gap metabolic acidosis</p><p class="bulletIndent1"><span class="glyph">●</span>Peak SIL greater than 500 mcg/dL (90 micromol/L) (see <a class="local">'Serum iron level interpretation'</a> above)</p><p class="bulletIndent1"><span class="glyph">●</span>Estimated ingested dose from visible pills on radiograph ≥60 mg/kg elemental iron (see <a class="local">'Toxic dose'</a> above)</p><p></p><p>Prior to administration of <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a>, consultation with a medical toxicologist and/or regional poison control center is recommended. Our approach is to administer deferoxamine initially as a continuous IV infusion at 15 mg/kg per hour and then incrementally increase by 5 to 10 mg/kg per hour every two to four hours, based upon the patient's clinical course, up to a maximum dose of 35 mg/kg per hour [<a href="#rid58">58</a>]. Criteria for increasing the dose include one or more of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent presence of vin rosé urine (which demonstrates ongoing chelation of iron with <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent or worsening metabolic acidosis</p><p class="bulletIndent1"><span class="glyph">●</span>Presence or development of other organ failure (eg, liver)</p><p></p><p>This approach is based upon the potential for early onset of multisystem organ failure in patients with a large overdose. Because of the kinetics of iron absorption and the possibility of lung toxicity with prolonged administration of <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a>, we suggest administering these larger doses of deferoxamine during the first 24 hours of treatment [<a href="#rid59">59</a>]. Other experts start at a lower dose of 5 mg/kg per hour and increase up to a maximum of 15 mg/kg per hour because of concern for potential adverse effects [<a href="#rid9">9</a>].</p><p>Adverse effects of IV <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> therapy include hypotension and the development of acute respiratory distress syndrome:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension can occur during the initial administration of <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a>. This effect appears to be related to rapid infusion and may be caused by histamine release [<a href="#rid59">59</a>]. It can generally be avoided by providing vigorous fluid resuscitation. This is preferable to slowing down the rate of the deferoxamine infusion, which should be avoided whenever possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute respiratory distress syndrome has been reported in patients who have received continuous infusions of <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> for 32 to 72 hours or more [<a href="#rid60">60,61</a>]. The etiology of lung toxicity is unknown. Some investigators have proposed that once iron has been removed from blood, deferoxamine binds with intracellular iron, resulting in cellular damage [<a href="#rid59">59</a>]. Others have challenged this theory and suggest that acute respiratory distress syndrome is secondary to the iron toxicity itself and not the deferoxamine.</p><p></p><p>The typical duration of therapy is about 24 hours. Recommendations for duration of <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> therapy have used resolution of clinical symptoms such as metabolic acidosis and shock as the endpoint for stopping therapy [<a href="#rid9">9,44</a>]. However, such nonspecific guidelines may result in prolonged treatment and increase the risk of lung toxicity from deferoxamine [<a href="#rid60">60,61</a>]. We suggest that the decision to stop deferoxamine therapy be made in consultation with a medical toxicologist and/or regional poison control center, taking into consideration the patient's clinical status and SIL. (See <a class="local">'Additional resources'</a> below.)</p><p>Although there are no randomized trials or case-control series in humans evaluating the efficacy of <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> as an antidote for iron overdose, anecdotal reports and case series describe improved clinical outcomes when IV deferoxamine is administered [<a href="#rid62">62,63</a>]. Studies in dogs have reported dramatically improved survival following lethal iron overdose for animals who received deferoxamine [<a href="#rid64">64,65</a>].</p><p class="headingAnchor" id="H33"><span class="h3">Elimination enhancement</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">Deferoxamine</a> remains the primary mode of therapy for patients with severe iron poisoning. (See <a class="local">'Deferoxamine'</a> above.)</p><p>Extracorporeal methods of iron removal are limited in effectiveness because they only remove free-circulating iron and must be started soon after ingestion before intracellular iron transport occurs. Extracorporeal removal with exchange transfusion or continuous veno-venous hemofiltration has been associated with good outcomes in cases of massive iron overdose and life-threatening toxicity where clinical deterioration persisted and SILs remained very high despite administration of <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> [<a href="#rid66">66,67</a>]. However, these measures carry a significant risk of complications such as bleeding and hemodynamic instability and should be regarded as novel and unreliable therapies of last resort for iron poisoning that should only be performed in consultation with a medical toxicologist.</p><p class="headingAnchor" id="H2478644718"><span class="h3">Liver transplantation</span><span class="headingEndMark"> — </span>Liver transplant may be lifesaving for patients with massive iron poisoning. For example, liver transplant was successful in two adolescent patients with large intentional iron overdose who developed rapidly progressive fulminant hepatic failure despite <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> therapy [<a href="#rid68">68</a>]. However, the specific timing and indications for liver transplant following severe iron poisoning are unclear. The decision to proceed with transplant requires a multidisciplinary approach that involves the medical toxicologist, gastroenterologist, intensivist, and transplant surgeon.</p><p class="headingAnchor" id="H35"><span class="h2">Mild poisoning</span><span class="headingEndMark"> — </span>Patients with mild poisoning symptoms (eg, nausea, self-limited vomiting, and/or mild abdominal pain) should be managed according to the results of initial ancillary studies  (<a class="graphic graphic_algorithm graphicRef131898" href="/z/d/graphic/131898.html" rel="external">algorithm 1A</a> and <a class="graphic graphic_algorithm graphicRef131897" href="/z/d/graphic/131897.html" rel="external">algorithm 1B</a>). Chelation with <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> is indicated for those who initially appear to have mild poisoning but whose findings indicate a high risk for moderate to severe poisoning (see <a class="local">'Deferoxamine'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Estimated ingested dose from visible pills on abdominal radiograph ≥60 mg/kg elemental iron</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated anion gap metabolic acidosis</p><p class="bulletIndent1"><span class="glyph">●</span>Peak SIL ≥500 mcg/dL (90 micromol/L)</p><p></p><p>In addition, GI decontamination is suggested for patients with toxic amounts of iron pills present on abdominal radiograph. (See <a class="local">'Gastrointestinal decontamination'</a> above.)</p><p>Patients with mild GI symptoms, normal baseline laboratory studies, few or no visible iron pills on abdominal radiograph, and SIL 350 to 500 mcg/dL may be observed. If symptoms improve or subside, they may be safely discharged home or, if an intentional ingestion, medically cleared for mental health evaluation [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H36"><span class="h2">Asymptomatic patients</span><span class="headingEndMark"> — </span>The management of patients who are initially asymptomatic after an iron ingestion is provided in the algorithm  (<a class="graphic graphic_algorithm graphicRef131897" href="/z/d/graphic/131897.html" rel="external">algorithm 1B</a>). Patients who remain asymptomatic during observation and have a peak SIL &lt;500 mcg/dL (90 micromol/L) may be discharged to home or, if the ingestion was intentional, medically cleared for a mental health evaluation.</p><p class="headingAnchor" id="H4123017488"><span class="h2">Special circumstances</span></p><p class="headingAnchor" id="H563380504"><span class="h3">Pregnant patients</span><span class="headingEndMark"> — </span>Indications for <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> therapy in pregnant patients are the same as those for other patients. Withholding deferoxamine when it is clinically indicated, out of a misguided notion that it may be toxic to the fetus, is a serious error that may have severe consequences for mother and fetus. (See <a class="local">'Deferoxamine'</a> above.)</p><p>Iron overdose during pregnancy is common but unique among overdoses because the fetus is protected from the direct effects of iron. Transplacental iron absorption is a saturable process. Consequently, significant accumulation of fetal iron does not occur [<a href="#rid70">70,71</a>]. The fetus is at risk only when the mother experiences clinical decompensation, such as hypotension, liver failure, or pulmonary failure.</p><p class="headingAnchor" id="H671377567"><span class="h3">IV iron overdose</span><span class="headingEndMark"> — </span>SILs following iatrogenic overdoses of IV iron preparations may be elevated well above 500 mcg/dL (90 micromol/L), but these levels have been associated with minimal or no subsequent toxicity in case reports as summarized below [<a href="#rid12">12,13</a>]. Furthermore, IV iron preparations are manufactured to avoid exceeding transferrin-binding capacity during IV administration and, when compared with oral iron preparations, appear to have a much higher toxic dose. (See <a class="local">'Kinetics'</a> above and <a class="local">'Toxic dose'</a> above.)</p><p>Thus, the decision to administer <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> to patients with IV iron overdoses should be based primarily on the development of significant clinical toxicity (eg, severe metabolic acidosis with shock or signs of hepatotoxicity) and not solely on the SILs [<a href="#rid12">12</a>]. Consultation with a poison center or medical toxicologist is warranted.</p><p>Minimal or no toxicity has occurred after iatrogenic IV iron overdose of 16 to 20 mg/kg of elemental iron despite very high SILs and no antidotal treatment:</p><p class="bulletIndent1"><span class="glyph">●</span>After receiving 1 g of <a class="drug drug_general" data-topicid="9004" href="/z/d/drug information/9004.html" rel="external">iron sucrose</a> (normal dose 200 mg), a patient developed transient dizziness and abdominal pain with normal vital signs. A rapid glucose was elevated (163 mg/dL), but white blood cell count and electrolytes were normal. SIL one hour after the infusion was 1301 mcg/dL (233 micromol/L). Because her symptoms had resolved, she was observed and remained asymptomatic and hemodynamically stable with normal liver function tests. The SIL returned to the normal range at approximately 24 hours [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Three patients given <a class="drug drug_general" data-topicid="8574" href="/z/d/drug information/8574.html" rel="external">iron dextran</a> 7 mg/kg instead of 0.7 mg/kg (10-fold dosing error) and another patient who received IV <a class="drug drug_general" data-topicid="9004" href="/z/d/drug information/9004.html" rel="external">iron sucrose</a> 1000 mg instead of 200 mg had minimal GI symptoms initially but became asymptomatic despite SILs up to 1000 mcg/dL (179 micromol/L ) [<a href="#rid13">13</a>].</p><p></p><p class="headingAnchor" id="H38"><span class="h3">Ingestion of chewable vitamins</span><span class="headingEndMark"> — </span>Any patient who may have ingested a toxic amount of iron must be referred to a hospital for evaluation and management. However, an evidence-based consensus guideline for the outpatient management of iron ingestion from the American Association of Poison Control Centers suggests that many children with unintentional ingestions of children's chewable vitamins with iron may be carefully observed at home with appropriate follow-up [<a href="#rid72">72</a>]. Children who develop persistent vomiting or diarrhea may need referral to the hospital for evaluation and treatment of dehydration.</p><p class="headingAnchor" id="H9897575"><span class="h1">PITFALLS IN MANAGEMENT</span><span class="headingEndMark"> — </span>Several pitfalls in the management of acute iron poisoning have been identified and should be avoided. These include [<a href="#rid16">16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Inaccurate calculation of dose of elemental iron ingested (see <a class="local">'Toxic dose'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate fluid repletion (see <a class="local">'Supportive care'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Failure to recognize patients in the latent phase (see <a class="local">'Clinical manifestations'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Excessive reliance on the serum iron level (SIL) to make management decisions in symptomatic patients or decisions regarding administration of <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> in asymptomatic patients (see <a class="local">'Serum iron level interpretation'</a> above and <a class="local">'Moderate to severe poisoning'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reliance on the total iron binding capacity (TIBC), a negative abdominal radiograph, or associated laboratory tests to predict toxicity (see <a class="local">'Evaluation'</a> above and <a class="local">'Laboratory studies'</a> above and <a class="local">'Plain radiograph of the abdomen'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Withholding <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> from pregnant patients (see <a class="local">'Pregnant patients'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> dose (see <a class="local">'Deferoxamine'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discontinuation of <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> on the basis of urine color alone (see <a class="local">'Deferoxamine'</a> above)</p><p></p><p class="headingAnchor" id="H39"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H67391547"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H40"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic dose</strong> – The ingested dose (mg/kg of <strong>elemental</strong> iron) and the iron formulation  (<a class="graphic graphic_table graphicRef106069" href="/z/d/graphic/106069.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef73372" href="/z/d/graphic/73372.html" rel="external">table 2</a>) determine the likely toxicity after an oral iron overdose. Ingestions ≥60 mg/kg of elemental iron are associated with serious toxicity and death. (See <a class="local">'Toxic dose'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The clinical features of acute iron poisoning after ingestion occur in five (often overlapping) phases (see <a class="local">'Clinical manifestations'</a> above)  (<a class="graphic graphic_table graphicRef61711" href="/z/d/graphic/61711.html" rel="external">table 4</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early gastrointestinal (GI) symptoms (persistent vomiting, hypovolemic shock, or altered mental status indicates moderate to severe poisoning)</p><p class="bulletIndent2"><span class="glyph">•</span>Latent (or relative stability)</p><p class="bulletIndent2"><span class="glyph">•</span>Shock and elevated anion gap metabolic acidosis</p><p class="bulletIndent2"><span class="glyph">•</span>Delayed hepatotoxicity/hepatic necrosis</p><p class="bulletIndent2"><span class="glyph">•</span>Remote gastric outlet obstruction</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and management </strong>– The evaluation and management of acute iron ingestion depends upon the presenting symptoms and estimated iron dose and is provided in the algorithms  (<a class="graphic graphic_algorithm graphicRef131898" href="/z/d/graphic/131898.html" rel="external">algorithm 1A</a> and <a class="graphic graphic_algorithm graphicRef131897" href="/z/d/graphic/131897.html" rel="external">algorithm 1B</a>) and the rapid overview table  (<a class="graphic graphic_table graphicRef61711" href="/z/d/graphic/61711.html" rel="external">table 4</a>). (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of iron poisoning is suspected based upon a history of iron ingestion and clinical manifestations of poisoning. It is confirmed by the presence of a toxic amount of visible iron pills on plain abdominal radiograph or a peak serum iron level (SIL) ≥500 mcg/dL (90 micromol/L). A peak SIL also helps to identify the level of expected toxicity after an oral overdose, which adds in management decisions. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Serum iron level interpretation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate to severe poisoning</strong> – The management of moderate to severe iron poisoning after acute ingestion consists of  (<a class="graphic graphic_algorithm graphicRef131898" href="/z/d/graphic/131898.html" rel="external">algorithm 1A</a> and <a class="graphic graphic_table graphicRef61711" href="/z/d/graphic/61711.html" rel="external">table 4</a>) (see <a class="local">'Management'</a> above and <a class="local">'Moderate to severe poisoning'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive care</strong> – Provide airway protection and respiratory support, as needed. Volume resuscitation to maintain euvolemia is essential. (See <a class="local">'Supportive care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrointestinal decontamination</strong> – The need for GI decontamination is determined by the number and location of iron pills seen on plain radiograph of the abdomen. We suggest whole-bowel irrigation (WBI) rather than no GI decontamination for patients who have potential for worsening toxicity based on the number of iron pills visible on plain abdominal radiograph (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Except for rare cases of massive oral iron overdose, the risk of gastric lavage usually outweighs the limited benefit. (See <a class="local">'Gastrointestinal decontamination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">Deferoxamine</a> – We recommend that patients, including pregnant patients, with any of the following indications receive iron chelation with intravenous (IV) deferoxamine (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>) (see <a class="local">'Deferoxamine'</a> above and <a class="local">'Pregnant patients'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Severe symptoms (lethargy or coma, hypovolemic shock, or persistent vomiting and/or diarrhea)</p><p class="bulletIndent3"><span class="glyph">-</span>Elevated anion gap metabolic acidosis</p><p class="bulletIndent3"><span class="glyph">-</span>Estimated ingested dose from visible pills on radiograph ≥60 mg/kg elemental iron</p><p class="bulletIndent3"><span class="glyph">-</span>Peak SIL ≥500 mcg/dL (90 micromol/L)</p><p></p><p class="bulletIndent2">Prior to administration of <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a>, we recommend consultation with a medical toxicologist and/or regional poison control center. Chelation of iron with deferoxamine should occur as soon as the potential for serious iron toxicity is apparent. Our approach to deferoxamine administration is provided above. (See <a class="local">'Deferoxamine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV iron overdose</strong> – SILs following iatrogenic overdoses of IV iron preparations may be elevated well above 500 mcg/dL with minimal or no subsequent toxicity. Thus, chelation of patients with IV iron overdoses should be based on the development of significant clinical toxicity (eg, severe metabolic acidosis with shock or signs of hepatotoxicity). (See <a class="local">'IV iron overdose'</a> above.)</p><p></p><p class="headingAnchor" id="H2626957478"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Rana Kronfol, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila) 2020; 58:1360.</a></li><li><a class="nounderline abstract_t">Morris CC. Pediatric iron poisonings in the United States. South Med J 2000; 93:352.</a></li><li class="breakAll">Osterhoudt, KC, Burns Ewald, et al. Toxicologic emergencies. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.979.</li><li><a class="nounderline abstract_t">Berkovitch M, Livne A, Lushkov G, et al. Acute iron intoxication: significant differences between sexes. Vet Hum Toxicol 1997; 39:265.</a></li><li><a class="nounderline abstract_t">Juurlink DN, Tenenbein M, Koren G, Redelmeier DA. Iron poisoning in young children: association with the birth of a sibling. CMAJ 2003; 168:1539.</a></li><li><a class="nounderline abstract_t">Anderson BD, Turchen SG, Manoguerra AS, Clark RF. Retrospective analysis of ingestions of iron containing products in the united states: are there differences between chewable vitamins and adult preparations? J Emerg Med 2000; 19:255.</a></li><li><a class="nounderline abstract_t">Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005; 23:589.</a></li><li><a class="nounderline abstract_t">Tenenbein M. Unit-dose packaging of iron supplements and reduction of iron poisoning in young children. Arch Pediatr Adolesc Med 2005; 159:557.</a></li><li><a class="nounderline abstract_t">Madiwale T, Liebelt E. Iron: not a benign therapeutic drug. Curr Opin Pediatr 2006; 18:174.</a></li><li><a class="nounderline abstract_t">Food and Drug Administration, HHS. Iron-containing supplements and drugs; label warning statements and unit-dose packaging requirements; removal of regulations for unit-dose packaging requirements for dietary supplements and drugs. Final rule; removal of regulatory provisions in response to court order. Fed Regist 2003; 68:59714.</a></li><li><a class="nounderline abstract_t">Kroeker S, Minuk GY. Intentional iron overdose: an institutional review. CMAJ 1994; 150:45.</a></li><li><a class="nounderline abstract_t">Biary R, Li L, Hoffman RS. Intravenous iron overdose: treat the patient not the number. Toxicol Commun 2019; 3:37.</a></li><li><a class="nounderline abstract_t">Beuhler MC, Wallace KL. Benign outcome with toxic serum iron levels following IV iron dextran overdose in three patients. Clin Toxicol (Phila) 2003; 41:738.</a></li><li><a class="nounderline abstract_t">Wood DM, Thomson AH, Lawes M, et al. Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child. Ther Drug Monit 2005; 27:405.</a></li><li><a class="nounderline abstract_t">Yassin M, Soliman AT, De Sanctis V, et al. A Young Adult with Unintended Acute Intravenous Iron Intoxication Treated with Oral Chelation: The Use of Liver Ferriscan for Diagnosing and Monitoring Tissue Iron Load. Mediterr J Hematol Infect Dis 2017; 9:e2017008.</a></li><li><a class="nounderline abstract_t">Mills KC, Curry SC. Acute iron poisoning. Emerg Med Clin North Am 1994; 12:397.</a></li><li><a class="nounderline abstract_t">Spiller HA, Wahlen HS, Stephens TL, et al. Multi-center retrospective evaluation of carbonyl iron ingestions. Vet Hum Toxicol 2002; 44:28.</a></li><li><a class="nounderline abstract_t">Klein-Schwartz W. Toxicity of polysaccharide--iron complex exposures reported to poison control centers. Ann Pharmacother 2000; 34:165.</a></li><li><a class="nounderline abstract_t">Klein-Schwartz W, Oderda GM, Gorman RL, et al. Assessment of management guidelines. Acute iron ingestion. Clin Pediatr (Phila) 1990; 29:316.</a></li><li><a class="nounderline abstract_t">Morse SB, Hardwick WE Jr, King WD. Fatal iron intoxication in an infant. South Med J 1997; 90:1043.</a></li><li class="breakAll">Velez, L, Delaney, K. Heavy metals. In: Emergency Medicine: Concepts and Clinical Practice, 5th edition, Marx, J, Hockberger, R, Walls, R (Eds), Mosby, St. Louis 2006. p.2418.</li><li><a class="nounderline abstract_t">Cançado RD, Muñoz M. Intravenous iron therapy: how far have we come? Rev Bras Hematol Hemoter 2011; 33:461.</a></li><li><a class="nounderline abstract_t">Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3:12.</a></li><li><a class="nounderline abstract_t">Tenenbein M. Toxicokinetics and toxicodynamics of iron poisoning. Toxicol Lett 1998; 102-103:653.</a></li><li><a class="nounderline abstract_t">Walker SE, Paton TW, Cowan DH, et al. Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteers. CMAJ 1989; 141:543.</a></li><li><a class="nounderline abstract_t">Robotham JL, Lietman PS. Acute iron poisoning. A review. Am J Dis Child 1980; 134:875.</a></li><li><a class="nounderline abstract_t">Harju E. Clinical pharmacokinetics of iron preparations. Clin Pharmacokinet 1989; 17:69.</a></li><li><a class="nounderline abstract_t">Riordan M, Rylance G, Berry K. Poisoning in children 3: common medicines. Arch Dis Child 2002; 87:400.</a></li><li><a class="nounderline abstract_t">Fawwaz RA, Winchell HS, Pollycove M, Sargent T. Hepatic iron deposition in humans. I. First-pass hepatic deposition of intestinally absorbed iron in patients with low plasma latent iron-binding capacity. Blood 1967; 30:417.</a></li><li><a class="nounderline abstract_t">Zimelman AP, Zimmerman HJ, McLean R, Weintraub LR. Effect of iron saturation of transferrin on hepatic iron uptake: an in vitro study. Gastroenterology 1977; 72:129.</a></li><li><a class="nounderline abstract_t">Reynolds LG. Diagnosis and management of acute iron poisoning. Baillieres Clin Haematol 1989; 2:423.</a></li><li><a class="nounderline abstract_t">Tenenbein M, Israels SJ. Early coagulopathy in severe iron poisoning. J Pediatr 1988; 113:695.</a></li><li><a class="nounderline abstract_t">Rosenmund A, Haeberli A, Straub PW. Blood coagulation and acute iron toxicity. Reversible iron-induced inactivation of serine proteases in vitro. J Lab Clin Med 1984; 103:524.</a></li><li><a class="nounderline abstract_t">Tenenbein M, Littman C, Stimpson RE. Gastrointestinal pathology in adult iron overdose. J Toxicol Clin Toxicol 1990; 28:311.</a></li><li><a class="nounderline abstract_t">Black J, Zenel JA. Child abuse by intentional iron poisoning presenting as shock and persistent acidosis. Pediatrics 2003; 111:197.</a></li><li><a class="nounderline abstract_t">Palatnick W, Tenenbein M. Leukocytosis, hyperglycemia, vomiting, and positive X-rays are not indicators of severity of iron overdose in adults. Am J Emerg Med 1996; 14:454.</a></li><li><a class="nounderline abstract_t">Lacouture PG, Wason S, Temple AR, et al. Emergency assessment of severity in iron overdose by clinical and laboratory methods. J Pediatr 1981; 99:89.</a></li><li><a class="nounderline abstract_t">Chyka PA, Butler AY. Assessment of acute iron poisoning by laboratory and clinical observations. Am J Emerg Med 1993; 11:99.</a></li><li><a class="nounderline abstract_t">Siff JE, Meldon SW, Tomassoni AJ. Usefulness of the total iron binding capacity in the evaluation and treatment of acute iron overdose. Ann Emerg Med 1999; 33:73.</a></li><li><a class="nounderline abstract_t">Thompson DF. Reassessment of measuring total iron binding capacity in acute iron overdose. Ann Pharmacother 1994; 28:63.</a></li><li><a class="nounderline abstract_t">Chyka PA, Butler AY, Holley JE. Serum iron concentrations and symptoms of acute iron poisoning in children. Pharmacotherapy 1996; 16:1053.</a></li><li><a class="nounderline abstract_t">Fine JS. Iron poisoning. Curr Probl Pediatr 2000; 30:71.</a></li><li><a class="nounderline abstract_t">Everson GW, Oudjhane K, Young LW, Krenzelok EP. Effectiveness of abdominal radiographs in visualizing chewable iron supplements following overdose. Am J Emerg Med 1989; 7:459.</a></li><li class="breakAll">Tenenbein, M. Iron. In: Clinical Toxicology, Ford, MD, Delaney, KA, Ling, LJ, et al. (Eds), WB Saunders, Philadelphia 2001. p.305.</li><li><a class="nounderline abstract_t">Position paper: whole bowel irrigation. J Toxicol Clin Toxicol 2004; 42:843.</a></li><li><a class="nounderline abstract_t">Thanacoody R, Caravati EM, Troutman B, et al. Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients. Clin Toxicol (Phila) 2015; 53:5.</a></li><li><a class="nounderline abstract_t">Tenenbein M. Whole bowel irrigation in iron poisoning. J Pediatr 1987; 111:142.</a></li><li><a class="nounderline abstract_t">Kaczorowski JM, Wax PM. Five days of whole-bowel irrigation in a case of pediatric iron ingestion. Ann Emerg Med 1996; 27:258.</a></li><li><a class="nounderline abstract_t">Palatnick W, Tenenbein M. Safety of treating poisoning patients with whole bowel irrigation. Am J Emerg Med 1988; 6:200.</a></li><li><a class="nounderline abstract_t">Everson GW, Bertaccini EJ, O'Leary J. Use of whole bowel irrigation in an infant following iron overdose. Am J Emerg Med 1991; 9:366.</a></li><li><a class="nounderline abstract_t">Landsman I, Bricker JT, Reid BS, Bloss RS. Emergency gastrotomy: treatment of choice for iron bezoar. J Pediatr Surg 1987; 22:184.</a></li><li><a class="nounderline abstract_t">Foxford R, Goldfrank L. Gastrotomy--a surgical approach to iron overdose. Ann Emerg Med 1985; 14:1223.</a></li><li><a class="nounderline abstract_t">Banner W Jr, Tong TG. Iron poisoning. Pediatr Clin North Am 1986; 33:393.</a></li><li><a class="nounderline abstract_t">Czajka PA, Konrad JD, Duffy JP. Iron poisoning: an in vitro comparison of bicarbonate and phosphate lavage solutions. J Pediatr 1981; 98:491.</a></li><li><a class="nounderline abstract_t">Czajka PA. Effect of bicarbonate, phosphate, and saline lavage solutions on the dissolution of ferrous sulfate tablets. J Toxicol Clin Toxicol 1984; 22:447.</a></li><li><a class="nounderline abstract_t">Geffner ME, Opas LM. Phosphate poisoning complicating treatment for iron ingestion. Am J Dis Child 1980; 134:509.</a></li><li><a class="nounderline abstract_t">Snyder BK, Clark RF. Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: a randomized controlled trial. Ann Emerg Med 1999; 33:400.</a></li><li><a class="nounderline abstract_t">Shannon M. Desferrioxamine in acute iron poisoning. Lancet 1992; 339:1601.</a></li><li><a class="nounderline abstract_t">Howland MA. Risks of parenteral deferoxamine for acute iron poisoning. J Toxicol Clin Toxicol 1996; 34:491.</a></li><li><a class="nounderline abstract_t">Ioannides AS, Panisello JM. Acute respiratory distress syndrome in children with acute iron poisoning: the role of intravenous desferrioxamine. Eur J Pediatr 2000; 159:158.</a></li><li><a class="nounderline abstract_t">Tenenbein M, Kowalski S, Sienko A, et al. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet 1992; 339:699.</a></li><li><a class="nounderline abstract_t">Tenenbein M. Benefits of parenteral deferoxamine for acute iron poisoning. J Toxicol Clin Toxicol 1996; 34:485.</a></li><li><a class="nounderline abstract_t">McEnery JT, Greengard J. Treatment of acute iron ingestion with deferoxamine in 20 children. J Pediatr 1966; 68:773.</a></li><li><a class="nounderline abstract_t">Whitten CF, Gibson GW, Good MH, et al. Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: clinical observations, experimental studies, and theoretical considerations. Pediatrics 1965; 36:322.</a></li><li><a class="nounderline abstract_t">Whitten CF, Chen YC, Gibson GW. Studies in acute iron poisoning. II. Further observations on desferrioxamine in the treatment of acute experimental iron poisoning. Pediatrics 1966; 38:102.</a></li><li><a class="nounderline abstract_t">Carlsson M, Cortes D, Jepsen S, Kanstrup T. Severe iron intoxication treated with exchange transfusion. Arch Dis Child 2008; 93:321.</a></li><li><a class="nounderline abstract_t">Milne C, Petros A. The use of haemofiltration for severe iron overdose. Arch Dis Child 2010; 95:482.</a></li><li><a class="nounderline abstract_t">Lai J, Chu J, Arnon R. Pediatric liver transplantation for fulminant hepatic failure secondary to intentional iron overdose. Pediatr Transplant 2017; 21.</a></li><li><a class="nounderline abstract_t">Bosse GM. Conservative management of patients with moderately elevated serum iron levels. J Toxicol Clin Toxicol 1995; 33:135.</a></li><li><a class="nounderline abstract_t">Curry SC, Bond GR, Raschke R, et al. An ovine model of maternal iron poisoning in pregnancy. Ann Emerg Med 1990; 19:632.</a></li><li><a class="nounderline abstract_t">Lacoste H, Goyert GL, Goldman LS, et al. Acute iron intoxication in pregnancy: case report and review of the literature. Obstet Gynecol 1992; 80:500.</a></li><li><a class="nounderline abstract_t">Manoguerra AS, Erdman AR, Booze LL, et al. Iron ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2005; 43:553.</a></li></ol></div><div id="topicVersionRevision">Topic 6498 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10798501" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pediatric iron poisonings in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10798501" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pediatric iron poisonings in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9311080" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Acute iron intoxication: significant differences between sexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796332" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Iron poisoning in young children: association with the birth of a sibling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11033271" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Retrospective analysis of ingestions of iron containing products in the united states: are there differences between chewable vitamins and adult preparations?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16140178" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15939855" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Unit-dose packaging of iron supplements and reduction of iron poisoning in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16601499" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Iron: not a benign therapeutic drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14567392" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Iron-containing supplements and drugs; label warning statements and unit-dose packaging requirements; removal of regulations for unit-dose packaging requirements for dietary supplements and drugs. Final rule; removal of regulatory provisions in response to court order.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8275408" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Intentional iron overdose: an institutional review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Intravenous iron overdose: treat the patient not the number</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Benign outcome with toxic serum iron levels following IV iron dextran overdose in three patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16044093" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28101313" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A Young Adult with Unintended Acute Intravenous Iron Intoxication Treated with Oral Chelation: The Use of Liver Ferriscan for Diagnosing and Monitoring Tissue Iron Load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8187690" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Acute iron poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11824771" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Multi-center retrospective evaluation of carbonyl iron ingestions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10676823" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Toxicity of polysaccharide--iron complex exposures reported to poison control centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2361339" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Assessment of management guidelines. Acute iron ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9347819" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Fatal iron intoxication in an infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9347819" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fatal iron intoxication in an infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23049364" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intravenous iron therapy: how far have we come?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24310424" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The pharmacokinetics and pharmacodynamics of iron preparations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022330" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Toxicokinetics and toxicodynamics of iron poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2776093" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6998282" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acute iron poisoning. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2673607" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical pharmacokinetics of iron preparations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12390910" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Poisoning in children 3: common medicines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6054660" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hepatic iron deposition in humans. I. First-pass hepatic deposition of intestinally absorbed iron in patients with low plasma latent iron-binding capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/830225" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effect of iron saturation of transferrin on hepatic iron uptake: an in vitro study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2736312" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Diagnosis and management of acute iron poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3171793" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Early coagulopathy in severe iron poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6421970" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Blood coagulation and acute iron toxicity. Reversible iron-induced inactivation of serine proteases in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2231830" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Gastrointestinal pathology in adult iron overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12509576" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Child abuse by intentional iron poisoning presenting as shock and persistent acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8765107" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Leukocytosis, hyperglycemia, vomiting, and positive X-rays are not indicators of severity of iron overdose in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7252671" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Emergency assessment of severity in iron overdose by clinical and laboratory methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8476468" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Assessment of acute iron poisoning by laboratory and clinical observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9867890" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Usefulness of the total iron binding capacity in the evaluation and treatment of acute iron overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8123966" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Reassessment of measuring total iron binding capacity in acute iron overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8947978" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Serum iron concentrations and symptoms of acute iron poisoning in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10742921" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Iron poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2757710" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effectiveness of abdominal radiographs in visualizing chewable iron supplements following overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2757710" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effectiveness of abdominal radiographs in visualizing chewable iron supplements following overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15533024" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Position paper: whole bowel irrigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25511637" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3598777" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Whole bowel irrigation in iron poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8629765" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Five days of whole-bowel irrigation in a case of pediatric iron ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3355628" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Safety of treating poisoning patients with whole bowel irrigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1675852" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Use of whole bowel irrigation in an infant following iron overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3820024" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Emergency gastrotomy: treatment of choice for iron bezoar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4061998" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Gastrotomy--a surgical approach to iron overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2870463" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Iron poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7205469" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Iron poisoning: an in vitro comparison of bicarbonate and phosphate lavage solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6530702" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effect of bicarbonate, phosphate, and saline lavage solutions on the dissolution of ferrous sulfate tablets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7377162" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Phosphate poisoning complicating treatment for iron ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10092717" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of magnesium hydroxide administration on iron absorption after a supratherapeutic dose of ferrous sulfate in human volunteers: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1351565" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Desferrioxamine in acute iron poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8800186" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Risks of parenteral deferoxamine for acute iron poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10664227" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Acute respiratory distress syndrome in children with acute iron poisoning: the role of intravenous desferrioxamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1347583" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8800185" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Benefits of parenteral deferoxamine for acute iron poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5910767" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment of acute iron ingestion with deferoxamine in 20 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5829325" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: clinical observations, experimental studies, and theoretical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5937669" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Studies in acute iron poisoning. II. Further observations on desferrioxamine in the treatment of acute experimental iron poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18356385" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Severe iron intoxication treated with exchange transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20501543" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The use of haemofiltration for severe iron overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28621023" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pediatric liver transplantation for fulminant hepatic failure secondary to intentional iron overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7897752" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Conservative management of patients with moderately elevated serum iron levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2344079" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : An ovine model of maternal iron poisoning in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1495721" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Acute iron intoxication in pregnancy: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16255338" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Iron ingestion: an evidence-based consensus guideline for out-of-hospital management.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
